KR102458964B1 - 코 투여 - Google Patents

코 투여 Download PDF

Info

Publication number
KR102458964B1
KR102458964B1 KR1020177002368A KR20177002368A KR102458964B1 KR 102458964 B1 KR102458964 B1 KR 102458964B1 KR 1020177002368 A KR1020177002368 A KR 1020177002368A KR 20177002368 A KR20177002368 A KR 20177002368A KR 102458964 B1 KR102458964 B1 KR 102458964B1
Authority
KR
South Korea
Prior art keywords
delete delete
nasal
delivery
sumatriptan
carbon dioxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177002368A
Other languages
English (en)
Korean (ko)
Other versions
KR20170035919A (ko
Inventor
퍼 기슬르 듀페슬랜드
라미 에이 마흐무드
존 메시나
Original Assignee
옵티노즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/315,132 external-priority patent/US11554229B2/en
Application filed by 옵티노즈, 인크. filed Critical 옵티노즈, 인크.
Publication of KR20170035919A publication Critical patent/KR20170035919A/ko
Application granted granted Critical
Publication of KR102458964B1 publication Critical patent/KR102458964B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/001—Particle size control
    • A61M11/003—Particle size control by passing the aerosol trough sieves or filters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0003—Details of inhalators; Constructional features thereof with means for dispensing more than one drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033—Details of the piercing or cutting means
    • A61M15/0041—Details of the piercing or cutting means with movable piercing or cutting means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0091—Inhalators mechanically breath-triggered
    • A61M15/0098—Activated by exhalation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/0007—Special media to be introduced, removed or treated introduced into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/02—Gases
    • A61M2202/0225—Carbon oxides, e.g. Carbon dioxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177002368A 2014-06-25 2015-06-25 코 투여 Active KR102458964B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/315,132 2014-06-25
US14/315,132 US11554229B2 (en) 2013-03-26 2014-06-25 Nasal administration
PCT/EP2015/064463 WO2015197798A1 (en) 2014-06-25 2015-06-25 Nasal administration

Publications (2)

Publication Number Publication Date
KR20170035919A KR20170035919A (ko) 2017-03-31
KR102458964B1 true KR102458964B1 (ko) 2022-10-25

Family

ID=53489954

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177002368A Active KR102458964B1 (ko) 2014-06-25 2015-06-25 코 투여

Country Status (14)

Country Link
EP (2) EP4233950B1 (enExample)
JP (2) JP6785227B2 (enExample)
KR (1) KR102458964B1 (enExample)
CN (1) CN106470724A (enExample)
AU (3) AU2015279154A1 (enExample)
BR (1) BR112016029926A2 (enExample)
CA (1) CA2953207A1 (enExample)
ES (1) ES3034743T3 (enExample)
IL (1) IL249585B (enExample)
MX (1) MX390453B (enExample)
RU (1) RU2016152090A (enExample)
SG (1) SG11201610685XA (enExample)
WO (1) WO2015197798A1 (enExample)
ZA (1) ZA201608785B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201713899D0 (en) * 2017-08-30 2017-10-11 Indosys Ltd Multi-dose medicament delivery device
US11744967B2 (en) * 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
CN108421138A (zh) * 2017-12-25 2018-08-21 宫本海 一种鼻腔雾化吸药器
US11259717B2 (en) * 2018-05-16 2022-03-01 Massachusetts Institute Of Technology Methods and apparatus for passive, proportional, valveless gas sampling and delivery
US12478292B2 (en) 2019-10-28 2025-11-25 The Research Foundation For The State University Of New York Devices, systems, and methods of monitoring arterial carbon dioxide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003518484A (ja) 1999-12-24 2003-06-10 グラクソ グループ リミテッド サルメテロールおよびプロピオン酸フルチカゾンの医薬用エアゾル製剤
JP2008509143A (ja) 2004-08-04 2008-03-27 シェーリング コーポレイション 気道疾患の処置のためのプレコナリルを含む薬学的処方物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9416884D0 (en) * 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
DK1555038T3 (da) 1999-03-03 2011-10-17 Optinose As Nasal administrationsindretning
GB0121568D0 (en) * 2001-09-06 2001-10-24 Optinose As Nasal delivery device
WO2001003645A2 (en) 1999-07-12 2001-01-18 Capnia, Incorporated Methods and apparatus for relieving headaches, rhinitis and other common ailments
US20070039615A1 (en) * 1999-11-08 2007-02-22 Capnia, Incorporated Methods and apparatus for treating rhinitis
AU2001272086A1 (en) 2000-02-28 2001-09-12 Capnia Incorporated Method and apparatus for transcutaneous infusion of carbon dioxide for local relief of pain and other ailments
ZA200306564B (en) * 2001-02-26 2004-10-15 Optinose As Nasal devices.
GB2403154B (en) * 2002-04-04 2007-01-24 Optinose As Nasal devices
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
GB0320171D0 (en) * 2003-08-28 2003-10-01 Optinose As Delivery devices
US20080190418A1 (en) * 2003-08-29 2008-08-14 Glaxo Group Limited Pharmaceutical Metered Dose Inhaler and Methods Relating Thereto
GB0503738D0 (en) * 2005-02-23 2005-03-30 Optinose As Powder delivery devices
GB0602980D0 (en) * 2006-02-14 2006-03-29 Optinose As Delivery device and method
GB0604319D0 (en) * 2006-03-03 2006-04-12 Optinose As Nasal delivery
GB2440316A (en) * 2006-07-25 2008-01-30 Optinose As Nasal inhaler with scrubber
ES2652415T3 (es) * 2006-12-26 2018-02-02 Shin Nippon Biomedical Laboratories, Ltd. Preparación para aplicación transnasal
GB2448193A (en) * 2007-04-05 2008-10-08 Optinose As Nasal delivery device
GB0719299D0 (en) * 2007-10-03 2007-11-14 Optinose As Nasal delivery devices
JP2011510964A (ja) * 2008-02-01 2011-04-07 ヴェクトゥラ リミテッド トリプタン類の肺用製剤
US20100196483A1 (en) * 2009-02-04 2010-08-05 Activaero Gmbh Research & Development Method for treatmentof severe and uncontrollable asthma
DE102011103347B4 (de) * 2011-05-27 2014-10-30 Meda Pharma Gmbh & Co. Kg Nasale pharmazeutische Formulierung
AU2013221302B2 (en) * 2012-02-16 2017-11-23 Capnia, Inc. Gas dispenser with diffusing nosepiece
WO2014155192A2 (en) * 2013-03-26 2014-10-02 Optinose As Nasal administration

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003518484A (ja) 1999-12-24 2003-06-10 グラクソ グループ リミテッド サルメテロールおよびプロピオン酸フルチカゾンの医薬用エアゾル製剤
JP2008509143A (ja) 2004-08-04 2008-03-27 シェーリング コーポレイション 気道疾患の処置のためのプレコナリルを含む薬学的処方物

Also Published As

Publication number Publication date
CN106470724A (zh) 2017-03-01
RU2016152090A (ru) 2018-07-27
EP4233950C0 (en) 2025-06-25
RU2016152090A3 (enExample) 2019-02-15
EP4233950B1 (en) 2025-06-25
IL249585B (en) 2021-04-29
MX2016017038A (es) 2017-05-01
ES3034743T3 (en) 2025-08-22
BR112016029926A2 (pt) 2017-08-22
KR20170035919A (ko) 2017-03-31
ZA201608785B (en) 2019-10-30
IL249585A0 (en) 2017-02-28
JP7090124B2 (ja) 2022-06-23
JP2020179191A (ja) 2020-11-05
AU2021215246A1 (en) 2021-09-09
AU2015279154A1 (en) 2017-01-12
WO2015197798A1 (en) 2015-12-30
EP4233950A1 (en) 2023-08-30
SG11201610685XA (en) 2017-01-27
CA2953207A1 (en) 2015-12-30
EP3160556A1 (en) 2017-05-03
JP2017520364A (ja) 2017-07-27
AU2020202029A1 (en) 2020-04-09
MX390453B (es) 2025-03-19
JP6785227B2 (ja) 2020-11-18

Similar Documents

Publication Publication Date Title
KR102345816B1 (ko) 코 투여
US20230166061A1 (en) Nasal administration
US12491325B2 (en) Drug delivery devices and methods for administering substances to a body cavity by heterogenous aerosolization for treatment of binge-eating disorders and/or obesity
JP7090124B2 (ja) 経鼻投与
RU2438710C2 (ru) Пригодный к распылению адгезивный к коже/слизистой оболочке препарат гелевого типа и система для введения с использованием препарата
WO2021245605A1 (en) Drug delivery devices and methods for administering substances to a body cavity by heterogenous aerosolization for treatment of binge-eating disorders and/or obesity
JP6945614B2 (ja) 経鼻投与
CA2908232C (en) Nasal administration of fluticasone and carbon dioxide
HK1221672B (en) Nasal administration
Shrewsbury Trends and Advancements in Drug Delivery: What is the" perfect" method of drug delivery?
PARDESHI et al. Indian Journal of Novel Drug Delivery

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4